Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome

References

• Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109:S2–S26.
   PubMed Web of Science ®Google Scholar
• Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–721.
   PubMed Web of Science ®Google Scholar
• Sperber AD, Dumitrascu D, Fukudo S, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2017;66:1075–1082.
   PubMed Web of Science ®Google Scholar
• Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393–1407.
   Web of Science ®Google Scholar
• Su AM, Shih W, Presson AP, et al. Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern. Neurogastroenterol Motil. 2014;26:36–45.
   PubMed Web of Science ®Google Scholar
• Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. Jama. 2015;313:949–958.
   PubMed Web of Science ®Google Scholar
• Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm. 2004;10:299–309.
   PubMedGoogle Scholar
• Paré P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther. 2006;28:1726–1735.
   PubMed Web of Science ®Google Scholar
• Doshi JA, Cai Q, Buono JL, et al. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. J Manag Care Spec Pharm. 2014;20:382–390.
   PubMed Web of Science ®Google Scholar
• Sethi S, Wadhwa V, LeClair J, et al. In-patient discharge rates for the irritable bowel syndrome - an analysis of national trends in the United States from 1997 to 2010. Aliment Pharmacol Ther. 2013;38:1338–1346.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Chang L, Bellamy N, et al. Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol. 2011;106:1749–1759.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Chang L, Schneck S, et al. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig Dis Sci. 2009;54:1532–1541.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43:541–550.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med. 1992;116:1009–1016.
   PubMed Web of Science ®Google Scholar
• Coffin B, Dapoigny M, Cloarec D, et al. Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome. Gastroenterol Clin Biol. 2004;28:11–15.
   PubMedGoogle Scholar
• Ricci J, Jhingran P, Harris W, et al. Impact of differences in severity of irritable bowel syndrome (IBS) on patients’ well being and resource use. Gastroenterology. 2001;120:A406.
   Web of Science ®Google Scholar
• Bijkerk CJ, de Wit NJ, Stalman WA, et al. Irritable bowel syndrome in primary care: the patients’ and doctors’ views on symptoms, etiology and management. Can J Gastroenterol. 2003;17:363–368.
   PubMed Web of Science ®Google Scholar
• Harris LA, Umar SB, Baffy N, et al. Irritable bowel syndrome and female patients. Gastroenterol Clin North Am. 2016;45:179–204.
   PubMed Web of Science ®Google Scholar
• Eswaran S, Goel A, Chey WD. What role does wheat play in the symptoms of irritable bowel syndrome? Gastroenterol Hepatol (NY). 2013;9:85–91.
   PubMedGoogle Scholar
• Quigley EM. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis. 2007;8:2–7.
   PubMed Web of Science ®Google Scholar
• Crowell MD, Harris L, Jones MP, et al. New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments. Curr Gastroenterol Rep. 2005;7:272–279.
   PubMedGoogle Scholar
• Halland M, Saito YA. Irritable bowel syndrome: new and emerging treatments. Bmj. 2015;350:h1622.
   PubMed Web of Science ®Google Scholar
• Srivastava D, Ghoshal U, Mittal RD, et al. Associations between IL-1RA polymorphisms and small intestinal bacterial overgrowth among patients with irritable bowel syndrome from India. Neurogastroenterol Motil. 2014;26:1408–1416.
   PubMed Web of Science ®Google Scholar
• Durbán A, Abellán JJ, Jiménez-Hernández N, et al. Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome. FEMS Microbiol Ecol. 2013;86:581–589.
   PubMed Web of Science ®Google Scholar
• Carroll IM, Ringel-Kulka T, Keku TO, et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011;301:G799–G807.
   PubMed Web of Science ®Google Scholar
• Durbán A, Abellán JJ, Jimenéz-Hernández N, et al. Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome. Environ Microbiol Rep. 2012;4:242–247.
   PubMed Web of Science ®Google Scholar
• Jalanka-Tuovinen J, Salojärvi J, Salonen A, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014;63:1737–1745.
   PubMed Web of Science ®Google Scholar
• Zhuang X, Xiong L, Li L, et al. Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32:28–38.
   PubMed Web of Science ®Google Scholar
• Ganji L, Alebouyeh M, Shirazi MH, et al. Dysbiosis of fecal microbiota and high frequency of Citrobacter, Klebsiella spp., and Actinomycetes in patients with irritable bowel syndrome and gastroenteritis. Gastroenterol Hepatol Bed Bench. 2016;9:325–330.
   PubMedGoogle Scholar
• Jeffery IB, O’Toole PW, Ohman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61:997–1006.
   PubMed Web of Science ®Google Scholar
• Tap J, Derrien M, Tornblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152:111–123, e118.
   PubMed Web of Science ®Google Scholar
• Cuomo R, Andreozzi P, Zito FP, et al. Irritable bowel syndrome and food interaction. World J Gastroenterol. 2014;20:8837–8845.
   PubMed Web of Science ®Google Scholar
• Posserud I, Strid H, Storsrud S, et al. Symptom pattern following a meal challenge test in patients with irritable bowel syndrome and healthy controls. United European Gastroenterol J. 2013;1:358–367.
   PubMed Web of Science ®Google Scholar
• Shekhar C, Monaghan PJ, Morris J, et al. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin. Gastroenterology. 2013;145:749–757.
   PubMed Web of Science ®Google Scholar
• Hayes P, Corish C, O’Mahony E, et al. A dietary survey of patients with irritable bowel syndrome. J Hum Nutr Diet. 2014;27:36–47.
   PubMed Web of Science ®Google Scholar
• Young E, Stoneham MD, Petruckevitch A, et al. A population study of food intolerance. Lancet. 1994;343:1127–1130.
   PubMed Web of Science ®Google Scholar
• Heizer WD, Southern S, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc. 2009;109:1204–1214.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Mazzawi T, Hausken T, et al. Interaction between diet and gastrointestinal endocrine cells. Biomed Rep. 2016;4:651–656.
   PubMed Web of Science ®Google Scholar
• Rajilić-Stojanović M, Jonkers DM, Salonen A, et al. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol. 2015;110:278–287.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Hatlebakk JG, Gilja OH, et al. The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome. Nutr J. 2015;14:92.
   PubMed Web of Science ®Google Scholar
• De Giorgio R, Volta U, Gibson PR. Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction? Gut. 2016;65:169–178.
   Web of Science ®Google Scholar
• Vazquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology. 2013;144:903–911.
   PubMed Web of Science ®Google Scholar
• Barmeyer C, Schumann M, Meyer T, et al. Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome. Int J Colorectal Dis. 2017;32:29–39.
   PubMed Web of Science ®Google Scholar
• Fritscher-Ravens A, Schuppan D, Ellrichmann M, et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. 2014;147:1012–1020.
   PubMed Web of Science ®Google Scholar
• Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013;145:320–328.
   PubMed Web of Science ®Google Scholar
• Bonder MJ, Tigchelaar EF, Cai X, et al. The influence of a short-term gluten-free diet on the human gut microbiome. Genome Med. 2016;8:45.
   PubMed Web of Science ®Google Scholar
• Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol. 2013;108:707–717.
   PubMed Web of Science ®Google Scholar
• Hayes PA, Fraher MH, Quigley EM. Irritable bowel syndrome: the role of food in pathogenesis and management. Gastroenterol Hepatol (N Y). 2014;10:164–174.
   PubMedGoogle Scholar
• Ringel-Kulka T, Choi CH, Temas D, et al. Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome. Am J Gastroenterol. 2015;110:1339–1346.
   PubMed Web of Science ®Google Scholar
• Halmos EP, Christophersen CT, Bird AR, et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64:93–100.
   PubMed Web of Science ®Google Scholar
• Bennet SMP, Bohn L, Storsrud S, et al. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs [published online ahead of print April 17, 2017]. Gut. 2017.
   PubMed Web of Science ®Google Scholar
• Böhn L, Störsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149:1399–1407.
   PubMed Web of Science ®Google Scholar
• Varju P, Farkas N, Hegyi P, et al. Low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet improves symptoms in adults suffering from irritable bowel syndrome (IBS) compared to standard IBS diet: A meta-analysis of clinical studies. PLoS One. 2017;12:e0182942.
   PubMed Web of Science ®Google Scholar
• Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146:67–75.
   PubMed Web of Science ®Google Scholar
• Rao SS, Yu S, Fedewa A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41:1256–1270.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Quigley EM, Lacy BE, et al. The effect of dietary intervention on irritable bowel syndrome: a systematic review. Clin Transl Gastroenterol. 2015;6:e107.
   PubMed Web of Science ®Google Scholar
• Eswaran SL, Chey WD, Han-Markey T, et al. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. Am J Gastroenterol. 2016;111:1824–1832.
   PubMed Web of Science ®Google Scholar
• Staudacher HM. Nutritional, microbiological and psychosocial implications of the low FODMAP diet. J Gastroenterol Hepatol. 2017;32(Suppl 1):16–19.
   PubMed Web of Science ®Google Scholar
• Muir JG, Gibson PR. The low FODMAP diet for treatment of irritable bowel syndrome and other gastrointestinal disorders. Gastroenterol Hepatol (N Y). 2013;9:450–452.
   PubMedGoogle Scholar
• Harkness EF, Harrington V, Hinder S, et al. GP perspectives of irritable bowel syndrome–an accepted illness, but management deviates from guidelines: a qualitative study. BMC Fam Pract. 2013;14:92.
   PubMed Web of Science ®Google Scholar
• Roberfroid M, Gibson GR, Hoyles L, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104:S1–63.
   PubMed Web of Science ®Google Scholar
• Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62:159–176.
   PubMed Web of Science ®Google Scholar
• Andriulli A, Neri M, Loguercio C, et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J Clin Gastroenterol. 2008;42:S218–S223.
   PubMed Web of Science ®Google Scholar
• Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol. 2009;15:2887–2892.
   PubMed Web of Science ®Google Scholar
• Balsari A, Ceccarelli A, Dubini F, et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica. 1982;5:185–194.
   PubMed Web of Science ®Google Scholar
• Wilson B, Whelan K. Prebiotic inulin-type fructans and galacto-oligosaccharides: definition, specificity, function, and application in gastrointestinal disorders. J Gastroenterol Hepatol. 2017;32:64–68.
   PubMed Web of Science ®Google Scholar
• Silk DB, Davis A, Vulevic J, et al. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:508–518.
   PubMed Web of Science ®Google Scholar
• Paineau D, Payen F, Panserieu S, et al. The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br J Nutr. 2008;99:311–318.
   PubMed Web of Science ®Google Scholar
• Mego M, Manichanh C, Accarino A, et al. Metabolic adaptation of colonic microbiota to galactooligosaccharides: a proof-of-concept-study. Aliment Pharmacol Ther. 2017;45:670–680.
   PubMed Web of Science ®Google Scholar
• Whorwell PJ. Do probiotics improve symptoms in patients with irritable bowel syndrome? Therap Adv Gastroenterol. 2009;2:37–44.
   PubMedGoogle Scholar
• Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics – Saccharomyces boulardii. Aliment Pharmacol Ther. 2007;26:767–778.
   PubMed Web of Science ®Google Scholar
• Williams MD, Ha CY, Ciorba MA. Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations. J Clin Gastroenterol. 2010;44:631–636.
   PubMed Web of Science ®Google Scholar
• Jalanka-Tuovinen J, Salonen A, Nikkila J, et al. Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS One. 2011;6:e23035.
   PubMed Web of Science ®Google Scholar
• Miller LE, Ouwehand AC. Probiotic supplementation decreases intestinal transit time: meta-analysis of randomized controlled trials. World J Gastroenterol. 2013;19:4718–4725.
   PubMed Web of Science ®Google Scholar
• Charbonneau D, Gibb RD, Quigley EM. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes. 2013;4:201–211.
   PubMed Web of Science ®Google Scholar
• Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581–1590.
   PubMed Web of Science ®Google Scholar
• O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–551.
   PubMed Web of Science ®Google Scholar
• Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2009;29:104–114.
   PubMed Web of Science ®Google Scholar
• Guyonnet D, Schlumberger A, Mhamdi L, et al. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutr. 2009;102:1654–1662.
   PubMed Web of Science ®Google Scholar
• Guyonnet D, Woodcock A, Stefani B, et al. Fermented milk containing Bifidobacterium lactis DN-173 010 improved self-reported digestive comfort amongst a general population of adults. A randomized, open-label, controlled, pilot study. J Dig Dis. 2009;10:61–70.
   PubMed Web of Science ®Google Scholar
• Eskesen D, Jespersen L, Michelsen B, et al. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12(R), on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. Br J Nutr. 2015;114:1638–1646.
   PubMed Web of Science ®Google Scholar
• Thijssen AY, Clemens CH, Vankerckhoven V, et al. Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2016;28:8–14.
   PubMed Web of Science ®Google Scholar
• Barrett JS, Canale KE, Gearry RB, et al. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J Gastroenterol. 2008;14:5020–5024.
   PubMed Web of Science ®Google Scholar
• Bafutto M, Almeida JR, Leite NV, et al. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii. Arq Gastroenterol. 2013;50:304–309.
   PubMedGoogle Scholar
• Cayzeele-Decherf A, Pelerin F, Leuillet S, et al. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: an individual subject meta-analysis. World J Gastroenterol. 2017;23:336–344.
   PubMed Web of Science ®Google Scholar
• Ng SC, Lam EF, Lam TT, et al. Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome. J Gastroenterol Hepatol. 2013;28:1624–1631.
   PubMed Web of Science ®Google Scholar
• Michail S, Kenche H. Gut microbiota is not modified by randomized, double-blind, placebo-controlled trial of VSL#3 in diarrhea-predominant irritable bowel syndrome. Probiotics Antimicrob Proteins. 2011;3:1–7.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17:687–696.
   PubMed Web of Science ®Google Scholar
• Wong RK, Yang C, Song GH, et al. Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: a randomized double-blinded placebo study. Dig Dis Sci. 2015;60:186–194.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:895–904.
   PubMed Web of Science ®Google Scholar
• Mezzasalma V, Manfrini E, Ferri E, et al. A randomized, double-blind, placebo-controlled trial: the efficacy of multispecies probiotic supplementation in alleviating symptoms of irritable bowel syndrome associated with constipation. Biomed Res Int. 2016;2016:4740907.
   PubMed Web of Science ®Google Scholar
• Yoon H, Park YS, Lee DH, et al. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr. 2015;57:129–134.
   PubMed Web of Science ®Google Scholar
• Yoon JS, Sohn W, Lee OY, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014;29:52–59.
   PubMed Web of Science ®Google Scholar
• Ki Cha B, Mun JS, Hwan CC, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol. 2012;46:220–227.
   PubMed Web of Science ®Google Scholar
• Min YW, Park SU, Jang YS, et al. Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis. World J Gastroenterol. 2012;18:4563–4569.
   PubMed Web of Science ®Google Scholar
• Sondergaard B, Olsson J, Ohlson K, et al. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol. 2011;46:663–672.
   PubMed Web of Science ®Google Scholar
• Ringel-Kulka T, Palsson OS, Maier D, et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol. 2011;45:518–525.
   PubMed Web of Science ®Google Scholar
• Simrén M, Öhman L, Olsson J, et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - a randomized, double-blind, controlled study. Aliment Pharmacol Ther. 2010;31:218–227.
   PubMed Web of Science ®Google Scholar
• Williams EA, Stimpson J, Wang D, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2009;29:97–103.
   PubMed Web of Science ®Google Scholar
• Kajander K, Myllyluoma E, Rajilic-Stojanovic M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008;27:48–57.
   PubMed Web of Science ®Google Scholar
• Bittner AC, Croffut RM, Stranahan MC, et al. Prescript-assist probiotic-prebiotic treatment for irritable bowel syndrome: an open-label, partially controlled, 1-year extension of a previously published controlled clinical trial. Clin Ther. 2007;29:1153–1160.
   PubMed Web of Science ®Google Scholar
• Bittner AC, Croffut RM, Stranahan MC. Prescript-Assist™ probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin Ther. 2005;27:755–761.
   PubMed Web of Science ®Google Scholar
• Colecchia A, Vestito A, La RA, et al. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol. 2006;52:349–358.
   PubMedGoogle Scholar
• Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–419.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chatterjee S, Chow EJ, et al. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51:1297–1301.
   PubMed Web of Science ®Google Scholar
• Basseri RJ, Weitsman S, Barlow GM, et al. Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol (N Y). 2011;7:455–493.
   PubMedGoogle Scholar
• Blondeau JM. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J Antimicrob Chemother. 2009;63:238–242.
   PubMed Web of Science ®Google Scholar
• Salix Pharmaceuticals. Xifaxan® (rifaximin) tablets, for oral use. Bridgewater (NJ): Salix Pharmaceuticals; 2015.
   Google Scholar
• Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.
   PubMed Web of Science ®Google Scholar
• Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39:1161–1168.
   PubMed Web of Science ®Google Scholar
• Shah E, Kim S, Chong K, et al. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med. 2012;125:381–393.
   PubMed Web of Science ®Google Scholar
• Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151:1113–1121.
   PubMed Web of Science ®Google Scholar
• Ghoshal UC, Srivastava D, Verma A, et al. Slow transit constipation associated with excess methane production and its improvement following rifaximin therapy: a case report. J Neurogastroenterol Motil. 2011;17:185–188.
   PubMed Web of Science ®Google Scholar
• Low K, Hwang L, Hua J, et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44:547–550.
   PubMed Web of Science ®Google Scholar
• Ghoshal U, Shukla R, Srivastava D, et al. Irritable bowel syndrome, particularly the constipation-predominant form, involves an increase in Methanobrevibacter smithii, which is associated with higher methane production. Gut Liver. 2016;10:932–938.
   PubMed Web of Science ®Google Scholar
• Kasir R, Zakko S, Zakko P, et al. Predicting a response to antibiotics in patients with the irritable bowel syndrome. Dig Dis Sci. 2016;61:846–851.
   PubMed Web of Science ®Google Scholar
• Acosta A, Camilleri M, Shin A, et al. Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome. Clin Transl Gastroenterol. 2016;7:e173.
   PubMed Web of Science ®Google Scholar
• Soldi S, Vasileiadis S, Uggeri F, et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. 2015;8:309–325.
   PubMed Web of Science ®Google Scholar
• Kim MS, Morales W, Hani AA, et al. The effect of rifaximin on gut flora and Staphylococcus resistance. Dig Dis Sci. 2013;58:1676–1682.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Fodor AA, Golden PL, et al. Characterization of stool microbiota in subjects with IBS-D receiving repeat treatments with rifaximin in the TARGET 3 study. Gastroenterology. 2015;148:S–655.
   Web of Science ®Google Scholar
• Zeber-Lubecka N, Kulecka M, Ambrozkiewicz F, et al. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. Gut Microbes. 2016;7:397–413.
   PubMed Web of Science ®Google Scholar
• Li YT, Cai HF, Wang ZH, et al. Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment Pharmacol Ther. 2016;43:445–457.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Masaoka T, Naganuma M, et al. Bifidobacterium-rich fecal donor may be a positive predictor for successful fecal microbiota transplantation in patients with irritable bowel syndrome. Digestion. 2017;96:29–38.
   PubMed Web of Science ®Google Scholar
• Halkjaer SI, Boolsen AW, Gunther S, et al. Can fecal microbiota transplantation cure irritable bowel syndrome? World J Gastroenterol. 2017;23:4112–4120.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66:569–580.
   PubMed Web of Science ®Google Scholar
• König J, Siebenhaar A, Hogenauer C, et al. Consensus report: faecal microbiota transfer - clinical applications and procedures. Aliment Pharmacol Ther. 2017;45:222–239.
   PubMed Web of Science ®Google Scholar
• De Palma G, Lynch MD, Lu J, et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med. 2017;9:1–14.
   Web of Science ®Google Scholar